Author:
Jorgensen Timothy J.,Tian Hui,Joseph Ingrid B. J. K.,Menon Krishna,Frost David
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference26 articles.
1. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501
2. Carlson DM, Steinberg JL, Gordon GB (2005) Targeting the unmet medical need: the Abbott Laboratories oncology approach. Clin Adv Hematol Oncol 3:703–710
3. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14-3-3s is required to prevent mitotic catastrophe after DNA damage. Nature 401:616–620
4. Taxotere-Patient Information Leaflet [ http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction = Search.Label_ApprovalHistory#apphist ]
5. Fox E, Adamson PC, Hagey A, Widemann BC, Maris JM, Cohn SL, Cai Y, Medina DM, Meek KA, Balis FM, et al (2005) Phase I trial of oral ABT-751 in pediatric patients: preliminary evidence of activity in neuroblastoma (NBL). J Clin Oncol 23:8527
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献